MED

Medifast Inc

Add to Watchlist

Advanced Chart

12.830

-0.02(-0.156%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

13.160

Open

12.920

VWAP

12.87

Vol

144.32K

Mkt Cap

141.02M

Low

12.740

Amount

1.86M

EV/EBITDA(TTM)

-1.35

Total Shares

10.94M

-21.44M

EV/OCF(TTM)

-5.16

P/S(TTM)

0.29

Medifast, Inc. is a health and wellness company. The Company is engaged in offering habit-based and coach-guided lifestyle solution, OPTAVIA, which provides people with a comprehensive approach to address obesity and support a healthy lifestyle. OPTAVIA provides coaching support along with community, tailored nutrition, and healthy habits, and helps people in their weight-loss journey through each stage of life. Through its collaboration with national virtual primary care provider LifeMD, Inc. and its affiliated medical group, customers have access to GLP-1 medications where clinically appropriate. It sells a variety of weight-loss, weight management and healthy living products all based on its proprietary formulas under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brands. Its product line includes approximately 79 consumable options, including bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

91.30M

-21.11%

-0.380

+442.86%

73.80M

-37.98%

-0.450

-550%

84.10M

-40%

-0.390

-211.43%

Estimates Revision

The market is revising No Change the revenue expectations for Medifast, Inc. (MED) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -2.21%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-2.21%

In Past 3 Month

1 Analyst Rating

16.91% Upside

Wall Street analysts forecast MED stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MED is 15.00 USD with a low forecast of 15.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

1 Hold

0 Sell

Hold

16.91% Upside

Current: 12.830

Low

15.00

Averages

15.00

High

15.00

16.91% Upside

Current: 12.830

Low

15.00

Averages

15.00

High

15.00

DA Davidson

Linda Bolton Weiser

Hold

Maintains

$17 → $17

2025-02-19

Reason

DA Davidson

Linda Bolton Weiser

Price Target

$17 → $17

2025-02-19

Maintains

Hold

Reason

DA Davidson

Linda Bolton Weiser

Sell

Hold

Upgrades

$17 → $17

2024-11-05

Reason

DA Davidson

Linda Bolton Weiser

Price Target

$17 → $17

2024-11-05

Upgrades

Sell

Hold

Reason

DA Davidson analyst Linda Bolton Weiser upgraded Medifast to Neutral from Underperform with a price target of $17, up from $16.50. With cash and investments of about $15.50 per share and no debt, the valuation "already seems to imply near zero for the remaining declining business," so share price downside could be more limited from here, the analyst tells investors.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Medifast Inc (MED.N) is -8.27, compared to its 5-year average forward P/E of 12.92. For a more detailed relative valuation and DCF analysis to assess Medifast Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

12.92

Current PE

-8.27

Overvalued PE

78.67

Undervalued PE

-52.84

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

7.54

Current EV/EBITDA

1.46

Overvalued EV/EBITDA

11.21

Undervalued EV/EBITDA

3.87

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

1.08

Current PS

0.38

Overvalued PS

1.66

Undervalued PS

0.49